Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Boost Brittle Bones Before Birth (BOOSTB4)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Sweden,Sweden,Sweden,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: Clinical research on regenerative medicine (H2020-PHC-2015-single-stage_RTD, 2015)
Start date: 2016-01-01
End date: 2022-12-31
Duration (months): 84.0
Total project cost (EUR): 8378755.75
EU funding (EUR): 6608754.5
Participants: 14
Project status: CLOSED

Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal mesenchymal stem cells (MSC) is a promising approach for treatment of OI. We receive regular requests for MSC transplantation from patients and their physicians; patient organisations support our approach. The principal objective of the BOOSTB4 project is to conduct a Phase I/II clinical trial of the safety and efficacy of pre- and/or postnatal MSC transplantation in the severest forms of OI (type III, severe type IV). Transplantation before birth at the onset of disease should lead to greater efficacy and engraftment with less rejection than transplantation after birth. Postnatal transplantation will be evaluated in cases where prenatal diagnosis was not made. The trial’s primary outcome is safety; secondary outcomes relate to efficacy (fracture frequency, growth, bone mineral density and quality of life). All patients will undergo molecular diagnosis to confirm OI before inclusion in the trial. Non-invasive prenatal diagnosis will be developed and validated. The BOOSTB4 consortium is led by experts in MSC, prenatal therapy and OI at the Karolinska Institutet (KI), which will also lead the international multicentre trial; five additional EU centres of excellence are included. Ethical and regulatory applications are underway to conduct this clinical trial. These are facilitated by the ethical and regulatory approvals for prenatal MSC transplantation in 10 cases of OI that have already been granted at KI. Successful prenatal transplantation represents a major step forward in the management of patients with severe OI, and beyond, to a range of other inherited birth defects.

Keywords: osteogenesis imperfecta,mesenchymal stem cells
Monitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells (BRCAstem)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-07-01
End date: 2022-06-30
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: CLOSED

Heterozygous germ line mutations in the breast cancer susceptibility genes (BRCA) 1 or 2 predispose carriers to breast, ovarian, pancreatic and prostate cancers. Significant evidence has accumulated in recent years on vulnerabilities specific to BRCA1/2-deficient tumours, leading to the development of personalized therapies, such as poly-ADP ribose polymerase (PARP) inhibitors. However, tumours develop resistance to these therapies, with tumour heterogeneity and enrichment in cancer stem cell (CSC) sub-population as an underlying resistance mechanism. How the genomic instability intrinsic to BRCA1/2 inactivation impacts on CSC survival and propagation during tumorigenesis and their relevance to the response to therapy has not yet been established. Previous results obtained in the host laboratory show that BRCA2 loss is associated, in the long term (28 days after BRCA2 abrogation), with upregulation of genes involved in metastasis and CSC markers, suggesting BRCA2-deficient cells can acquire metastatic and tumour-initiating capacity. In the current project proposal, we intend to study at single-cell resolution the relationship between CSCs and the response to PARP inhibitors and ionizing radiation (IR) in cancer cell lines and patient-derived xenografts (PDXs) lacking BRCA2 . We will develop a combined single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) experimental approach to characterize BRCA2-deficient CSC subpopulations and to monitor the spatio-temporal dynamics of the CSC signature. This will enable us not only to understand the molecular mechanisms driving cell plasticity in models of BRCA2 inactivation, but also to evaluate the CSC impact on the response of BRCA-mutated tumours to current targeting therapies.

Keywords: brca1 and brca2 genes,dna damage
Disruptive Technology for the Global Laundry Equipment Market (LIRON-2020)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: United Kingdom
Call: Open Disruptive Innovation Scheme (implemented through the SME instrument) (H2020-SMEINST-1-2014, 2014)
Start date: 2014-10-01
End date: 2015-03-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

LIRON 2020 addresses the €Multi-Billion global market for domestic laundry equipment with a highly innovative, disruptive technology that will revolutionise the industry and provide significant economic, lifestyle and environmental benefits. There are an estimated 840 million domestic washing machines in use worldwide, with predictions of 36% growth by 2020 and 62% by 2030. Together, these washing machines account for approximately 2% of the total residential sector electricity consumption and utilise about 19 billion cubic metres of water per year. With energy and water prices soaring there is a constant drive towards more energy- and water-efficient laundry technology within the home. In addition, there is a further demand from consumers to make their lives easier and improve the time-efficiency of their laundry process. Woodrow Scientific Limited (WSL) was established to address this need, inventing methods and apparatus that enable “on demand” cleaning of garments with massively reduced electricity and water consumption and without the fabric wear and tear of conventional washing machines. The technical feasibility of WSL’s LIRON™ technology has been proven with the world’s first laser-laundered shirts and informal consumer research has identified a market appetite for the unique technology and lifestyle benefits it offers. The LIRON-2020 project presents an opportunity for WSL to further evaluate the market feasibility and identify the optimum route to commercialising the technology for this >€1Billion global market. Horizon 2020 funding will enable the company to further validate the performance benefits of its unique technology, strengthen and expand its IP portfolio and prepare the business strategy to leverage further investment / partnership and (potentially) Phase 2 project funding required to exploit the technology globally.

Keywords: disruptive innovation,lasers,photonics,new market generation,environmental
EURopean Endeavour for Chimeric Antigen Receptor Therapies (EURE-CART)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Italy,Germany,Germany,Spain,Italy,France,Czechia
Call: New therapies for chronic diseases (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2021-06-30
Duration (months): 54.0
Total project cost (EUR): 5903146.0
EU funding (EUR): 5903146.0
Participants: 11
Project status: CLOSED

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for starting the conduction of a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the AGC Biologics (formerly Molmed SpA), which is uniquely endowed in the EU with the knowhow and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

Keywords: cancer as a model chronic disease,cancer gene therapy,immunotherapy,innovative personalised medicines,involvement of national regulatory authorities for accelerating atmp approval
Novel Processes and Equipment in Composite Repair Technology (NEWCORT)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Research and Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Greece,Greece,Sweden,Greece,France
Call: Structural bonded repair of monolithic composite airframe (H2020-CS2-CFP01-2014-01, 2014)
Start date: 2016-01-01
End date: 2019-12-31
Duration (months): 48.0
Total project cost (EUR): 588745.0
EU funding (EUR): 588745.0
Participants: 5
Project status: CLOSED

NEWCORT will develop and validate novel processes and equipment for the repair of composite airframes. Three key stages in the bonded composite repair procedure were identified, namely material removal & surface preparation, heating for polymerization of patch and positive pressure application for improved compaction of patch layers. In all three stages novel processes will be developed, either through integration of innovations already existing within the proposing consortium or through research focused in targeted areas. For material removal, developments include process optimization to enable close tolerance applications for curved thick composite structures, potentially combined with scarfed pre-cured patches, potential simplification of stepping requirements and adaptation of material removal equipment to most frequent geometries (e.g. fuselage curvature). Novel heating processes and equipment will focus on the polymerization of new types of resins (e.g. M20 at 140oC), possibly including thermoplastic materials, through application of new power supply control logic, dielectric sensors for curing and viscosity monitoring, heating flux sensors for improved curing control, heating mats with embedded thermocouples and dielectric sensors, simulation software for selection of blankets and thermocouples installation topology, as well as development of Quick Composite Repair (QCR) kits for most frequent aircraft repair cases. Finally, the development of positive pressure application equipment for flat / curved structures will be studied, together with optimized pressure measurement devices and control software, mountable to most frequent repair cases (e.g. composite fuselage curvature). The application of such novel processes in real-life aeronautical environment will be guaranteed, through the simultaneous development of all the associated application equipment, resulting in TRL-7 solutions, ready to undergo a full validation campaign during the last project steps.

Keywords: bonded composite repair,composite materials,curing
Proof of Concept – Arctic Data Management System Beta version – capacity building for interpretation and data management system of the Arctic-related data and knowledge (Arctic Data Management System) (ADMS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Iceland
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 96328.75
EU funding (EUR): 96328.75
Participants: 1
Project status: CLOSED

The specific objective is to design the Proof of Concept (PoC) - Arctic Data Management System (ADMS) Beta version - the first phase necessary for the implementation of the ADMS - a system of interpreting and managing Arctic-related data and knowledge. ADMS identifies and retrieves Arctic-related data and knowledge from multiple databases, adapts it to a common standard and provides interpretation, visualization and retrieval of the standardized data to an end-user. ADMS is based on state-of-the-art data intelligence tools including geographic information system (GIS), metadata catalogues, and interpretation and visualization tools. In the interpretation of data the system combines the highest level of technical and human elements to provide end-users with the highest quality and most appropriate data solutions. The Proof of Concept - ADMS Beta version - is a realization of a method to demonstrate the feasibility of the proposed data management system and to technically verify that the concept has the potential of being used by customers. By recruiting an Innovation Associate the Arctic Portal aims at demonstrating the feasibility of the proposed data management and interpretation system of the Arctic-related data and knowledge. The Innovation Associate will help the Arctic Portal to: (i) position itself as a hub for monitoring network’s Data Management System, Arctic interlinked data, analysis models and decision support tools; (ii) strengthen and improve the existing Global Terrestrial Network for Permafrost (GTN-P) Data Management System (DMS) located in Akureyri and designed by Arctic Portal; (iii) generalize and apply similar data management tools for other Global Monitoring Networks.

Keywords: arctic,data management,data interpretation
Providing an open collaborative space for digital biology in Europe (EOSC-Life)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: EOSC ecosystem
Action type: Research and Innovation actions
Countries involved: Germany,Austria,Austria,Germany,Germany,Spain,Spain,Spain,Spain,Italy,Italy,Italy,Israel,Germany,Germany,Spain,Italy,Italy,Italy,Germany,Switzerland,Finland,Norway,Belgium,Finland,Finland,Norway,Belgium,Greece,Slovenia,Belgium,France,France,Czechia,Czechia,Czechia,Netherlands,Netherlands,Netherlands,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Portugal,United Kingdom,Portugal
Call: Connecting ESFRI infrastructures through Cluster projects (H2020-INFRAEOSC-2018-2, 2018)
Start date: 2019-03-01
End date: 2023-08-31
Duration (months): 54.0
Total project cost (EUR): 26145996.25
EU funding (EUR): 26145996.25
Participants: 70
Project status: SIGNED

EOSC-Life brings together the 13 Biological and Medical ESFRI research infrastructures (BMS RIs) to create an open collaborative space for digital biology. It is our joint response to the challenge of analysing and reusing the prodigious amounts of data produced by life-science. Managing and integrating this data is beyond the capabilities of most individual end-users and institutes. By publishing data and tools in a Europe-wide cloud EOSC-Life aims to bring the capabilities of big science projects to the wider research community. Federated user access (AAI) will allow transnational resource access and authorisation. EOSC-Life establishes a novel access model for the BMS RI: through EOSC scientists would gain direct access to FAIR data and tools in a cloud environment available throughout the European Research Area. EOSC-Life will make BMS RIs data resources FAIR and publish them in the EOSC following guidelines and standards (e.g. EDMI). Overall this will drive the evolution of the RI repository infrastructure for EOSC and integration of the BMS RI repositories. EOSC-Life will implement workflows that cross disciplines and RI boundaries and address the needs of interdisciplinary science. Through open hackathons and bring-your-own-data events we will co-create EOSC-Life with our user communities , providing a blueprint for how the EOSC supports wide-spread and excellent data-driven life science research. EOSC-Life will address the data policies needed for human research data under GDPR. Interoperable provenance information describe history of sample and data to ensure reproducibility and adherence to regulatory requirements. The goal of the EOSC-Life project is to make sure that life-scientists can find, access and integrate life-science data for analysis and reuse in academic and industrial research. EOSC-Life will transform European life-science by providing an open, continent-scale, collaborative and interdisciplinary environment for data science.

Keywords: eosc,biological medical research infrastructures,bms ri,esfr,cloud,data resources,gdpr
M-H70 2.0 Hydrogen pressure gas regulators specifically designed for Fuel Cell Vehicles (M-H70)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Italy
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-08-01
End date: 2018-11-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Car pollution is one of the major causes of global warming. Therefore, there is an urgent demand for smarter and more sustainable automotive solutions. Alternative fuels for fossil fuels are the key solution. Among the alternative fuel, the hydrogen is the most affordable and environmentally friendly solution. Thereby, the improvement in the fuel cell stack is a must. Metatron is a leader company regarding components of alternative fuels such as pressure regulator for CNG and LNG. Currently, for the first time, hydrogen gas regulators are developing specifically for fuel cell vehicles at Metatron. The traditional H2 pressure regulators are designed for medical or chemical applications, and they have a single architecture using diaphragm technology. The innovative Metatron´s solution lies in an H2 pressure regulator designed exclusively for FCV with double stage architecture, piston technology and made of aluminium alloy which works at 700 barG. These unique features offer large mileage (up to 800 km), durability (15 years guarantee without maintenance), lightness (<1,8 kg), reliability (+/- 1 barG output pressure variation) and safety. M-H70 2.0 solution will benefit Auto OEMs specialized in FCV, H2 cylinder suppliers and fuel cell stack suppliers. Our close collaboration with some of the future customers i.e. BMW, Saic Motor or Sunrise Power, and the huge interest in our solution from Ford or Yutong reflect that M-H70 is extremely attractive to the target end-users. Within 5 years of its launch to the market, more than 40.000 units are expected to be sold, obtaining €9.9 million of accumulated profit and creating 12 jobs. In the future, a fuel line hydrogen pressure regulator will be developed and packaged in a compact and robust box ready to install in the fuel cell vehicle system.

Keywords: hydrogen pressure regulator,fuel cell vehicle,piston technology,double stage architecture,output pressure constant,700 barg
CEreal REnaissance in Rural Europe: embedding diversity in organic and low-input food systems (CERERE)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive agri-food sector for a safe and healthy diet
Action type: Coordination and support actions
Countries involved: Ireland,Italy,Spain,Italy,Belgium,Finland,Hungary,France,France,Denmark,Denmark,United Kingdom,United Kingdom,United Kingdom
Call: Thematic Networks compiling knowledge ready for practice (H2020-RUR-2016-1, 2016)
Start date: 2016-11-01
End date: 2019-10-31
Duration (months): 36.0
Total project cost (EUR): 1997550.0
EU funding (EUR): 1997550.0
Participants: 16
Project status: CLOSED

Organic/low input cereal food systems in the EU are emerging in answer to the sustainability crisis of the conventional agri-food sector. “Alternative” systems are based on local, decentralized approaches to production and processing, regard to quality and health, and short supply chains for products with strong local identities. Diversity is deeply embedded in these food systems, from the agro-biodiversity grown in farmers’ fields, which improves resilience and adaptation, to diverse approaches, contexts and actors in food manufacturing and marketing. Diversity thus becomes a cross-sectoral issue, underlying innovations in the agronomic, processing, and marketing phases which respond to consumers’ demand for healthy products. CERERE’s objective is to foster and speed up these innovations to strengthen the economic, social and environmental sustainability of these cereal food systems, consolidate links among practitioners and with researchers, further enhance the resilience of agro-ecosystems and make the overall sector more competitive and better recognized by society. By creating a multi-actor network of researchers and communities of practice, by adopting a bottom-up approach, and by liaising with EIP-AGRI Operational Groups, CERERE will synthesize, share and disseminate existing best practices, research results and co-innovative solutions in organic/low-input cereal food systems, focusing particularly on agro-biodiversity and the associated values of quality and health. Through its activities and training products, CERERE will address the key issues and most urgent needs of these systems: availability/ management of adapted germplasm, use of rotations, soil fertility, weed competitiveness and crop protection strategies, quality-oriented processing techniques, alternative marketing schemes. For each of these, CERERE will identify opportunities for better integrating science and practice, paving the way for more dynamic interactions between the two domains.

Keywords: agrobiodiversity,bottom up approach,cereal,co innovation,multiactor approach,operational groups